Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 15/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14730210 | 0.92 | RET (0.37) | CKS1BSKP1SKP2RETDPP4 | |
| SCHEMBL14723078 | 0.92 | RET (0.37) | CKS1BSKP1SKP2RETDPP4 | |
| SCHEMBL14723500 | 0.90 | NTRK1 (0.42) | CKS1BSKP1SKP2RETDPP4 | |
| SCHEMBL14730294 | 0.90 | NTRK1 (0.42) | CKS1BSKP1SKP2RETDPP4 | |
| SCHEMBL14730335 | 0.83 | DPP4 (0.38) | CKS1BSKP1SKP2RETDPP4 | |
| SCHEMBL14730278 | 0.82 | NTRK1 (0.43) | RETDPP4 | |
| SCHEMBL14722263 | 0.82 | NTRK1 (0.43) | RETDPP4 | |
| SCHEMBL5924109 | 0.81 | DPP4 (0.43) | DPP4DPP7DPP8 | |
| SCHEMBL609468 | 0.80 | NTRK1 (0.40) | RET | |
| SCHEMBL1720753 | 0.80 | NTRK1 (0.40) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013026587-A1 | 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |